ArticleMolecular biotechnology2026
Development of an ELISA Test with High Diagnostic Accuracy for SARS-COV-2 Using Recombinant Nucleocapsid Protein Expressed in E. coli.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study aimed to produce a recombinant N protein to develop an enzyme-linked immunosorbent assay (ELISA). A recombinant pET28a vector was constructed, and E. coli BL 21 was transformed for recombinant protein expression. After SDS-PAGE analysis, we approved recombinant N protein expression and purification using western and dot-blotting tests. In ELISA setup tests, 2.5 µg/ml of N protein and 1:100 serum dilution was determined as optimum concentrations for anti-N IgG antibody. In validation tests, 47 out of 51 negative and 46 out of 51 positive samples were determined negative and positive, respectively, using our developed ELISA. According to the Receiver Operating Characteristic (ROC) curve analysis based on the Youden index, the sensitivity and specificity of the developed test were 92% and 90.38%, respectively. An ELISA test with the recombinant SARS-CoV-2 N protein was developed with high specificity and sensitivity for the clinical diagnosis of SARS-CoV-2 infection.
Indexed as
Identifiers
40193039What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.